Lakefront Biotherapeutics | GLPG - Cost Of Sales


Lakefront Biotherapeutics reported EUR4.8M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
argenx SE USD 145M 24M Jun/2026
AstraZeneca USD 2.52B 2.73B Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
Genmab DKK 84M 19M Jun/2026
Gilead Sciences USD 1000M 445M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
GRIFOLS EUR 1.17B 90M Jun/2026
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
Incyte USD 104.96M 457K Jun/2026
Merck EUR 2.07B 219M Mar/2026
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
Novartis USD 3.71B 251M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Sanofi EUR 3.02B 656M Jun/2026
UCB EUR 1.07B 146M Dec/2025
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026